- 5,353$2.3B
1
- 11,322$5.3B
2
- 7,000$1.5B
3
- 2,000$293.6M
4
- 14,522$9.6B
5
- 840$283.6M
6
Exeltis - Business Information
Manufacturing · New Jersey, United States · 4,000 Employees
Exeltis is a fast-growing division of Madrid-based Insud Pharma, an integrated health sciences group. It has developed a leading position in the women's health sector, where it continues to discover, develop, produce and seek new medicines and medical devices to improve the health and wellbeing of women around the world. Exeltis strives to provide care for women throughout their lives. Exeltis offers a broad portfolio of products to respond to patients' needs in Women's Health including contraception, pregnancy, birth, and menopause and has expanded its research in recent years to Central Nervous System (CNS), ophthalmology and endocrinology.Read More
View Company Info for Free
Who is Exeltis
Headquarters
Phone Number
Website
Revenue
Industry
Top Competitors of Exeltis
Exeltis Org Chart
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Exeltis News & Media
Lupin Signs Promotional Agreement with Exeltis on SOLOSEC® (secnidazole) expanding access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis
BALTIMORE, Jan. 27, 2022 /PRNewswire/ -- Lupin Pharmaceuticals Inc., (Lupin), and Exeltis USA Inc. announced a promotional agreement for Exeltis to promote SOLOSEC® along with Exeltis' existing line of Women's Health products, further enhancing value to OBGYNs and their patients. SOLOSEC®...IntelGenx Announces Market Launch of RIZAPORT® in Spain
SAINT LAURENT, Quebec, Sept. 07, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Exeltis Healthcare S.L. (“Exeltis”), its commercialization partner in the European Union (“EU”) for RIZAPORT®, a unique for the treatment of acute migraines, has launched the product in Spain.Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum’s Novel Preclinical Candidate Targeting Woman’s Gynecological Conditions
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, has entered into an agreement with Exeltis (“Exeltis”) (a division of the global pharmaceutical group Insud Pharma) to develop, manufacture and commercialize a novel preclinical candidate from Aptorum in the following territories: the European Union and Latin America (with an option tIntelGenx and Exeltis Healthcare S.L. Expand RIZAPORT® Commercialization Agreement to Include the European Union
- Agreement Adds 26 Countries to Commercial Territory, with Initial Sales Expected in Early 2021-
Frequently Asked Questions regarding Exeltis
Exeltis is a fast-growing division of Madrid-based Insud Pharma, an integrated health sciences group. It has developed a leading position in the women's health sector, where it continues to discover, develop, produce and seek new medicines and medical devices to improve the health and wellbeing of women around the world. Exeltis strives to provide... Read More